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Abstract
Background: MicroRNAs (miRNAs) are small non-coding RNAs that participate in the spatiotemporal regulation of
messenger RNA (mRNA) and protein synthesis. Recent studies have shown that some miRNAs are involved in the
progression of nasopharyngeal carcinoma (NPC). However, the aberrant miRNAs implicated in different clinical
stages of NPC remain unknown and their functions have not been systematically studied.
Methods: In this study, miRNA microarray assay was performed on biopsies from different clinical stages of NPC.
TargetScan was used to predict the target genes of the miRNAs. The target gene list was narrowed down by
searching the data from the UniGene database to identify the nasopharyngeal-specific genes. The data reduction
strategy was used to overlay with nasopharyngeal-specifically expressed miRNA target genes and complementary
DNA (cDNA) expression data. The selected target genes were analyzed in the Gene Ontology (GO) biological
process and Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathway. The microRNA-Gene-Network
was build based on the interactions of miRNAs and target genes. miRNA promoters were analyzed for the
transcription factor (TF) binding sites. UCSC Genome database was used to construct the TF-miRNAs interaction
networks.
Results: Forty-eight miRNAs with significant change were obtained by Multi-Class Dif. The most enriched GO terms
in the predicted target genes of miRNA were cell proliferation, cell migration and cell matrix adhesion. KEGG
analysis showed that target genes were significantly involved in adherens junction, cell adhesion molecules, p53
signalling pathway et al. Comprehensive analysis of the coordinate expression of miRNAs and mRNAs reveals that
miR-29a/c, miR-34b, miR-34c-3p, miR-34c-5p, miR-429, miR-203, miR-222, miR-1/206, miR-141, miR-18a/b, miR-544,
miR-205 and miR-149 may play important roles on the development of NPC. We proposed an integrative strategy
for identifying the miRNA-mRNA regulatory modules and TF-miRNA regulatory networks. TF including ETS2, MYB,
Sp1, KLF6, NFE2, PCBP1 and TMEM54 exert regulatory functions on the miRNA expression.
Conclusions: This study provides perspective on the microRNA expression during the development of NPC. It
revealed the global trends in miRNA interactome in NPC. It concluded that miRNAs might play important
regulatory roles through the target genes and transcription factors in the stepwise development of NPC.
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Genetic and environmental factors are involved in the
tumorigenesis and development of nasopharyngeal carci-
noma (NPC). NPC is commonly diagnosed late due to
vague early symptoms [1]. At first consultation, 70% of
cases were diagnosed as cervical lymph node metastasis
and 20-35% were diagnosed as long distant metastasis
[2-4]. It is important to elucidate the cellular and mole-
cular mechanisms of dynamic development of NPC. It is
extremely necessary to identify the biomarkers and
detect the high-risk factors in the progression of NPC.
microRNAs (or ‘miRNAs’, which are small noncoding
RNA molecules) as post-transcriptional regulators have
been a hotspot in research for their involvement in bio-
logical processes and tumour development [5,6]. They
have been found to regulate genes involved in diverse
biological functions, including development, differentia-
tion, proliferation, and stress response. The dysregula-
tion of miRNAs appears to play a crucial role in cancer
pathogenesis where they exert their effect as oncogenes
or as tumour suppressors [7]. A growing number of
miRNAs have been implicated in carcinogenic process.
A significant number of miRNAs have been mapped to
cancer-associated genomic regions. Expression of the
miRNA let-7 has been correlated with prognosis in lung
cancer and found to regulate Ras in the same tumor [8].
Very recently, miR-10b has been shown to contribute to
metastasis in breast cancer [9].
To date, several miRNAs have been shown to target
specific mRNAs to regulate the progression of NPC.
miR-216b [10], miR-218 [11], miR-26a/b [12,13], miR-
10b [14], let-7 [15], miR-141 [16], miR-200a [17] have
been shown to have tumor suppressive functions in
NPC. Not surprisingly, Epstein-Barr virus-encoded miR-
NAs have oncogenic properties [18-20]. It is well known
that EBV infection has been identified as an essential
factor in the carcinogenesis of NPC [21]. EBV-infection
severely deregulates the miRNA profile of the host cell
[22]. Several EBV encoded miRNAs were expressed at
levels similar to highly abundant human miRNAs. EBV-
encoded miRNAs such as miR-BART1-5p, miR-
BART16, and miRBART17-5p, are intimately involved
in processes leading to NPC [23,24]. The microRNA
array has been performed by independent labs, identify-
ing several differentially-expressed miRNAs in NPC
[25-27]. The development of NPC is a multistage pro-
cess, depending on spatial and temporal control of gene
expression. Thus, it is unclear whether dysregulation of
microRNA expression is an aberrant event that occurs
during NPC progression. The dynamic regulatory roles
of miRNA need to be explored. A key to understanding
the role of miRNA is to determine when and where
they are expressed [28]. Here, we studied the miRNA
dynamic expression profiles in different clinical stages of
NPC and NPC lymph node metastasis. The predicted
miRNA target genes were compared to the cDNA
expression in the Gene Expression Omnibus (GEO)
(GSE12452). We found that a series of genes and miR-
NAs play an important role in the stepwise development
of NPC.
Similar to protein-coding genes, the transcription of
miRNAs is also regulated by transcription factors (TFs)
[29,30], an important class of gene regulators that act at
the transcriptional level. The normal regulation of miR-
NAs by TFs is critical, and aberrant regulation of miR-
NAs by TFs can cause phenotypic variations and
diseases [31]. Therefore, a TF-miRNA regulation data-
base would be helpful for understanding the mechan-
isms by which TFs regulate miRNAs and then
understanding their contribution to diseases.
In this study, the miRNA-gene interaction and tran-
scription factor-miRNA interaction network were also
described. Our study gives perspective on miRNAs
expression in the stepwise development of NPC. It
revealed the global trends in miRNA interactome in
NPC.
Methods
Patient samples and laser-capture microdissection
Snap-frozen NPC biopsies were obtained from NPC
patients and normal, healthy nasopharyngeal epithelial
samples from biopsy-negative cases were used as con-
trol. The criteria of clinical staging of NPC samples was
based on the 2008 staging system of NPC, which was
established in 2008 according to NPC 92 and AJCC sta-
ging system [32,33]. NPC samples in clinical staging I-
IV were used (numbers I to IV, with IV having greater
progression). Samples were collected from Xiangya Sec-
ond Hospital, Central South University. The patients
were informed about the sample collection and had
signed informed consent forms. Collections and use of
tissue samples were approved by the ethical review com-
mittees of Xiangya Second Hospital (Additional file 1).
Laser capture microdissection was used to separate the
cancer tissues from the normal tissues. Samples were
first frozen-sectioned by using a LEICA CM 1900 cryo-
microtome. Phase contrast images were acquired using
LEICA CTR 6500 microscope.
miRNA microarrays
Total RNA was extracted using Trizol
® reagent (Invitro-
gen) from samples. Two hundred nanograms (200 ng)
of total RNA from each sample were used for the fol-
low-up microarray. Poly(A) polymerase (PAP) was used
to add a stretch of Poly-A tail to the 3’ end of each
sequence in total RNA. The Ambion Illumina TotalPrep
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lated cDNA. MicroRNA expression profiling kit contains
primers for 1146 human miRNAs. The biotinylated
cDNAs were hybridized with microRNA-specific oligo-
nucleotides. The unbinding oligos were washed away
and followed by the extension and ligation reaction.
Polymerase Chain Reactions (PCR) were performed with
fluorescently labelled universal primers, followed by
hybridizing of the fluorescently labelled, single-stranded
PCR products to capture beads. The fluorescent signals
were then detected by Illumina’s iScan System. All steps
were performed according to Illumina’s instructions
manual.
Bioinformatics analysis
1. Multi-Class Dif (RVM-F test)
Raw data from each array were analyzed using Multi-
Class Dif (RVM-F test) which is applicable to small sam-
ple size analysis for multiple groups. The RVM F-test
was applied to screen the dynamic differentially-
expressed genes. The detailed methods were applied as
previously described [34-36].
2. Gene Ontology (GO)
The TargetScan database was used to predict the target
gene of miRNAs. To understand the functions of pre-
dicted target genes, we used the ontology classification
of genes based on gene annotation and summary infor-
mation available through DAVID (Database for Annota-
tion, Visualization and Integrated Discovery). The
predicted target genes were assigned to functional
groups based on molecular function, biological processes
and specific pathways.
3. TF-miR-net
miRNAs sequence was mapped to the genome in the
Sanger database. The Jemboss software was used to
examine the alignment of sequences of pre-miRs and
putative transcription factor binding sequences. A gen-
ome browser database was used to build the relationship
of transcription factors and miRNAs network. An adja-
cency matrix was implemented in Java (programming
language) according to the binding of pre-miRNAs and
transcription factors. The network’s core transcription
factor is the most important centre with the biggest
degree [37,38]. The Pearson correlation analysis [37] is
used to measure the regulatory ability of transcription
factors by calculating the correlation between transcrip-
tion factors and the miRNAs.
4. MicroRNA-gene-network
The MicroRNA-Gene-Network was based on the inter-
actions of miRNAs and target genes [39]. Twenty miR-
NAs of interest were built determined by pathways
extracted from KEGG as primary nodes-networks. The
significance of relationship of the miRNAs and target
genes network was evaluated by the number of nodes in
the network with degree greater than 10. In the Micro-
RNA-Gene-Network, the circle represents gene and the
square represents MicroRNA, and their relationship was
represented by one edge.
Quantitative reverse transcription-polymerase chain
reaction analysis
Total RNA was extracted using Trizol
® reagent (Invitro-
gen) from samples. The primers for RT-PCR to detect
miRNA were designed based on the miRNA sequences
provided by the Sanger Center miRNA Registry. The
primers were synthesized and purified by the Shanghai
Gene-Pharma Co. (Shanghai, China). RT reactions were
performed by means of the iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA). Real-time PCR was performed
on the BIO-RAD IQTM5 Multicolor Real-Time PCR
detection System (Bio-Rad). The qPCR cycle was 98°C
for 2 min., 40 cycles of 95°C for 15 sec., 60°C for 30 sec.
Final melt-curve analysis (60°-95°C) was included. The
standard curve was produced with slopes at approxi-
mately -3.32 (~100% efficiency); miRNA PCR quantifica-
tion used 2
ΔΔct method against the U6 for
normalization. mRNA PCR quantification used 2
ΔΔct
method against the GAPDH for normalization. The data
are representative of the means of three experiments.
RT-PCR primers:
miR-18a-F: TAAGGTGCATCTAGTGCAGATAG
miR-18b-F: TAAGGTGCATCTAGTGCAGTTAG
mR-141-F: TAACACTGTCTGGTAAAGATGG
miR-149-F: TCTGGCTCCGTGTCTTCACTCCC
miR-99a-F: AACCCGTAGATCCGATCTTGTG
miR-99b-F: CACCCGTAGAACCGACCTTGCG
miR-206-F: TGGAATGTAAGGAAGTGTGTGG
miR-34b-F: CAATCACTAACTCCACTGCCAT
miR-34c-3-F: AATCACTAACCACACGGCCAGG
miR-34c-5-F: AGGCAGTGTAGTTAGCTGATTGC
miR-29b-F: TAGCACCATTTGAAATCAGTGTT
miR-29c-F: TAGCACCATTTGAAATCGGTTA
miR-429-F: TAATACTGTCTGGTAAAACCGT
miR-32-F: TATTGCACATTACTAAGTTGCA
miR-181c-F: AACATTCAACCTGTCGGTGAGT
U6-F: ATTGGAACGATACAGAGAAGATT
U6-R: GGAACGCTTCACGAATTTG
ATM-F: GGACAGTGGAGGCACAAAAT
ATM-R: GTGTCGAAGACAGCTGGTGA
BCL2-L2-F: TCGCCCTGTGGATGACTGA
BCL2-L2-R: CCAGGAGAAATCAAACAGAGGC
CDH1-F: CGAGAGCTACACGTTCACGG
CDH1-R: CGAGAGCTACACGTTCACGG
E2F3-F: CACTTCCACCACCTCCTGTT
E2F3-R: TGACCGCTTTCTCCTAGCTC
YY1-F: CAAGAAGTGGGAGCAGAAGC
YY1-R: CTGCCAGTTGTTTGGGATCT
MYB-F: ACAGTCATTTGATGGGTT
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Dcier-Fe AAGGAAGCTGGCAAACAAGAe
Dcier-R: AAAACGAACCACCAAGTTGCe
Smad2-F: CGAAATGCCACGGTAGAAAT
Smad2-R: CCAGAAGAGCAGCAAATTCC
KLF6-F: CACGAGACCGGCTACTTCTC
KLF6-R: CGGATTCCTCCTTTTTCTCC
GAPDH-F: GAGTCAACGGATTTGGTCGT
GAPDH-R: TTGATTTTGGAGGGATCTCG
Results
1. miRNA expression profile in the stepwise development
of NPC
In order to identify miRNAs associated with the step-
wise development of NPC, miRNA microarrays were
performed. We analyzed the temporal patterns of miR-
NAs expression profiles during the development of
NPC. Samples were taken from a range of tumors of dif-
ferent stages. 6 cases of normal, 4 cases of each stage I
or II, III, IV and 4 cases of lymph node metastasis were
taken. The microdissection was performed with Methyl
Green staining to separate tumor cells to non-tumor
cells (Figure 1A). The Illumina microRNA Expression
Profiling Assay was performed. The raw data of miRNA
array can be downloaded from the National Center for
Biotechnology Information-Gene Expression Omnibus
(GEO) (GEO:GSE32906). From MicroRNA profiling,
after separating signal from noise, we obtained 766 miR-
NAs. Microarray data showed that 48 miRNAs were dif-
ferentially expressed with significant change in tumor
samples compared to normal samples (Multi-class Dif
multiple comparison test RVM-F test, P < 0.05, FDR <
0.05) [34-36]. Differentially expressed miRNAs between
various stages of NPC and normal nasopharyngeal
epithelia were clustered by Cluster3.0, as shown in the
Figure 1B. Using the dendrogram-based methods for
Clustering, the samples can be further separated into
five subgroups on hierarchical clustering based on their
similar expression patterns, which were correlated with
the NPC clinic stages. The results showed that the
expression pattern of miRNAs from the different clinical
stages can be distinguished from each other (Figure 1B).
We identified differentially-expressed miRNAs between
clinical stages, in which 12 miRNAs differentially
expressed between stage I-II and normal, 15 miRNAs
between stage III and normal, 20 miRNAs between
stage IV and normal, 37 miRNAs between lymph node
metastasis and normal, as shown in Table 1. Our study
revealed dynamic miRNA expressions, which were clas-
sified into 6 different patterns (Figure 1C). In pattern 1,
miRNA expressions gradually decreased during the
development of NPC. In pattern 5, miRNA expressions
gradually increased during the development of NPC. In
pattern 6, miRNA expressions dramatically increased in
the lymph node metastasis.
These results suggested that these miRNAs might play
important roles in the stepwise development of NPC.
2. Target gene prediction of miRNAs and gene function
analysis
Putative target genes of 48 differentially expressed
miRNAs were searched with online algorithms for
miRNA target prediction (TargetScan). More than a
thousand target genes were predicted for the 48 miR-
NAs. The predicted target gene lists were narrowed
down by searching the data from ftp://ftp.ncbi.nih.gov/
repository/UniGene/ to find the nasopharyngeal- speci-
fic genes.
We compared gene expression profiles of NPC biopies
and miRNA expression profiles done above. The expres-
sion data (GSE12452) from biopsies of NPC and non-
malignant controls were downloaded from the National
Center for Biotechnology Information-Gene Expression
Omnibus (GEO). Putative target genes of miRNAs dif-
ferentially expressed in NPC biopsies, which was consis-
tent with the miRNA expression were shown in Table 2.
We found that such as miR-29c and miR-34c-5 were
down regulated, their target gene NDST1 and MMP2
were upregulated in NPC, miR-1/206 and their target
C D H 1 ,S M A D 4 ,P D C D 1 0 ,T G F B R 3a r ea l s oc o n s i s t e n t
to each other, miR-18a/b and their target ATM and
Samd4 also showed the coordinate expression. After
microRNAs target filtering, the miRNAs which regulate
the development of NPC through target gene regulation
may be narrowed down. The selected genes were ana-
lyzed in the context of Gene Ontology (GO) biological
process and Kyoto Encyclopedia of Genes and Genomes
(KEGG) biological pathway using the molecular annota-
tion. To assess the function of the predicted target gene,
we evaluated the frequency of specific gene ontology
terms among the predicted nasopharyngeal specific tar-
get genes of the 48 miRNAs using DAVID. The most
enriched GO terms in the predicted targets genes of
miRNA were cell proliferation, cell migration and cell
matrix adhesion (Table 3). The predicted target genes
were also analyzed by Kyoto Encyclopedia of Genes and
Genomes (KEGG). As shown in Table 4, these target
genes were significantly involved in adherens junction,
pathway in cancer, cell adhesion molecules, p53 signal-
ing pathway et al.I td e m o n s t r a t e dt h a tm i R N A sw i t h
significant change are involved in regulation of target
genes related to the development of NPC. These
miRNA:gene interactions were built into a bipartite net-
work (the miRNAome) (Figure 2).
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Page 4 of 12Figure 1 miRNA expression profile in the stepwise development of NPC. (A) The microdissection was performed with Methyl Green
staining to separate tumor cells to non-tumor cells; (B)Hierarchical clustering result of 48 differentially-expressed miRNAs. Each row represents
the expression profile of a miRNA across 22 samples and each column represents a sample. The sample IDs and clinical stages information are
listed above the ‘heatmap’. Red and green colors respectively indicate either higher and lower expression levels of the miRNA. Samples are well
separated into control and NPC patient groups except three. Using the dendrogram-based methods for clustering, the samples can be further
separated into five subgroups on hierarchical clustering, which were correlated with the NPC clinic stages. (C) Dynamic miRNA expressions were
classified into 6 different patterns.
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genes
As mentioned above, we integrated the miRNA expres-
sion profile and cDNA expression profile. We narrowed
down the candidate miRNA list which may play impor-
tant roles on the development of NPC. To confirm
microarray data, real-time RT-PCR experiments were
conducted using specific primers for 15 miRNAs (miR-
206, miR-141, miR-149, miR-34b, miR-34c-3, miR-34c-
5, miR-18a, miR-18b, miR-99a, miR-99b, miR-429, miR-
32, miR-181c, miR-29b and miR-29c) in 38 NPC cases
and 10 normal nasopharyngeal epithelial tissue cases.
We confirmed the down-regulation of the miR-34 family
(miR-34b, miR-34c-3, miR-34c-5, miR-429) and up-reg-
ulation of miR-17-92 (miR-18a/b) cluster. The dynamic
expression patterns obtained with real-time RT-PCR
were consistent with the microarray results (Figure 3).
Furthermore, we also performed the real-time PT-PCR
to evaluate the expression target genes. As shown in
Figure 4, the expression of the selected target genes of
the miRNAs showed the reverse correlation with the
miRNA expression. We found that target genes such as
CDH1 (miR-1/206), ATM (miR-18a/b), KLF6 (miR-18a/
b and miR-181c), Smad2(miR-18a/b, miR-1/206 and
miR-149), Dicer(miR-18a/b) were down expressed with
the development of NPC, while BCL2L2 (miR-29a/b/c
and miR-203), E2F3(miR-34b/c and miR-429), ETS2
(miR-429), MYB(miR-429) and YY1 (miR-29a/b/c and
miR-34b/c) were overexpressed during the development
of NPC.
4. The miRNA transcriptional network for NPC
development
Although the expression of miRNAs and their targets is
often highly correlated, anti-correlations exist because of
miRNA feedback loops and upstream regulators,
Table 1 The aberrantly expressed miRNAs in the different multi-stages of NPC
Stage Down-regulated miRNAs Up-regulated miRNAs
I-II hsa-miR-449a, hsa-miR-34c-3p, hsa-miR-32, hsa-miR-34b, hsa-miR-
625, hsa-miR-34b* hsa-miR-34c-5p
hsa-miR-455-5p, hsa-miR-199b-5p, hsa-miR-409-3p, hsa-miR-411, hsa-
miR-107
III hsa-miR-34b, hsa-miR-34c-3p, hsa-miR-34b*, hsa-miR-449a, hsa-miR-
34c-5p
hsa-miR-17-5p:9.1, hsa-miR-107, hsa-miR-409-3p, hsa-miR-18a, hsa-
miR-339-5p, hsa-miR-99a, hsa-miR-34a*, hsa-miR-411, hsa-miR-455-
5p, hsa-miR-149
IV hsa-miR-32, hsa-miR-449a, hsa-miR-99a, hsa-miR-199b-5p, hsa-miR-99b, hsa-miR-339-5p, hsa-
miR-708, hsa-miR-200a*, hsa-miR-18b, hsa-miR-20a*, hsa-miR-409-3p,
hsa-miR-107, hsa-miR-18a*, hsa-miR-17-5p:9.1, hsa-miR-34a*, hsa-miR-
503, hsa-miR-455-5p, hsa-miR-411, hsa-miR-18a, hsa-miR-149
Metastasis hsa-miR-449a, hsa-miR-32, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-
186, hsa-miR-130b, hsa-miR-34c-3p, hsa-miR-34b, hsa-miR-181c,
hsa-miR-361-3p, hsa-miR-429, hsa-miR-625, hsa-miR-335, hsa-let-7c,
hsa-miR-29c, hsa-miR-421, hsa-miR-141, hsa-miR-29a
hsa-miR-708, hsa-miR-149, hsa-miR-20a*, hsa-miR-34a*, hsa-miR-99a,
hsa-miR-107, hsa-let-7d*, hsa-miR-483-3p, hsa-miR-18b, hsa-miR-455-
5p, hsa-miR-199b-5p, hsa-miR-193a-5p, hsa-miR-99b, hsa-miR-503,
hsa-miR-18a, hsa-miR-409-3p, hsa-miR-411, hsa-miR-1, hsa-miR-206
Table 2 Putative target genes of differentially expressed miRNAs in NPC biopsies, which was consistent with the
mRNA expression
miRNA microarray cDNA microarray
miRNA Expression Target gene expression
hsa-miR-1/206 up API5, PCDH17, SMAD2, MTSS1, PDCD10, PDCD4, SMAD4 down
hsa-miR-141 up PDCD4, MTSS1, ARHGAP24, SIAH1, PTEN down
hsa-miR-149 up TP63, SMAD2, CNTNAP2 down
hsa-miR-18a/b up DICER1, GIGYF2, STK4, RABGAP1, NOTCH2, NEDD9, ATM, SMAD2, NAV1, FOSL2, CAMKK2, STK4, BTG3,
UBE2Z, IRF2, LIN54, HIF1A, RABGAP1, CCDC88A, ETV6, CCND2
down
hsa-miR-205 up CADM1, MORF4L2, PTEN, SMAD1, SMAD4, TP53BP2 down
hsa-miR-544 up AKT2, CADM1, CDH1, SMAD4 down
hsa-miR-99a/b up BMPR2, IGF1R, THAP2 down
hsa-miR-203 down BCL2L2, ESR1, HBEGF, HBP1, HSPB8, IGFBP5, ITGA2, LPP, MAP3K1 MKL2, MLLT4, SOCS3 up
hsa-miR-222 down ESR1, ITGB8, MBD2, MIA3, MLL, SOCS3, TET2 up
hsa-miR-29a/c down BCL2L2, HBEGF, HBP1, HSPG2, ITGB1, LAMC2, LTBR, MIB1, MLF1, MMP2, NDST1, SVEP1 up
hsa-miR-34b down BTRC, CTNNA1, CUL3, CYLD, ESR1, HIPK1, ITGA2, ITM2B, MKL2, MXD1, PAPD5, PPP1CB, SMAD3 up
hsa-miR-34c-3p down DCBLD2, FOXN3, IKZF1, NPTN PAFAH1B1, USP10, YY1 up
hsa-miR-34c-5p down ARHGAP1, ARHGEF3, BCL11B, C16orf5, CNTNAP1, FOXN3, FUT8, IL6R, ITGB8, ITSN1, JAG1, MLL2, NDST1,
NOTCH2, NPNT, PPFIA1, PTPRM, PVRL1, SERPINE1, VCL, YY1
up
hsa-miR-429 down MIB1, MLL5, NDST1, RHOA, RND3 up
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miRNA-target genes network, the TF-miRNA transcrip-
tional interactions need to be elucidated. The predicted
transcription factors binding to the miRNAs with the
degree greater than 10 were shown in Table 5. Among
them, 7 transcription factors were found differentially
expressed in clinical stage I-II; 8 in stage III; 14 in stage
IV and 21 in lymph node metastasis, compared to the
normal samples. Seven TFs including ETS2, MYB, Sp1,
KLF6, NFE2, PCBP1 and TMEM54 were shown in the
middle of network, regulating most of the selected miR-
NAs (Figure 5). The larger triangles represent the more
miRNAs which are regulated. The numbers of miRNA
regulated by TF were represented by degrees. These
transcription factor-miRNA interactions were built into
a network.
We further investigated the TF-miRNAs-target genes
feedback loop by integrating the TF-miRNA networks
and miRNA-target genes networks. The possible regula-
tory feedback loops were shown in Table 6. These tran-
scription factors may repress their own translation
through induction of miRNAs as a negative regulatory
feedback loop. This strategy combines paired expression
profiles of TF, miRNAs and mRNAs in computational
target predictions.
Discussion
While the process events that result in NPC remain
unclear, global transcriptome analysis, including miR-
NAome [40,41], is a useful tool to investigate dynamic
change of molecular networks between different clinical
stages. Although the microRNA array has been per-
formed by two independent labs [25,26], the dynamic
miRNA expression during the development of NPC
remains unknown. NPC is a multistage process that
usually takes decades to develop. It is necessary to inves-
tigate the molecular events during the process. In our
study, samples from different clinical stages of NPC
were analyzed by the microRNA array. Microdissection
was performed to ensure the purity of cancer tissues.
Usually microarray techniques provide a valuable way of
Table 3 GO Functional Annotation of the target genes
Term Count % PValue FDR
up-regulated target gene GO functional annotation
GO:0022610~biological adhesion 19 2.496715 2.93E-09 4.71E-06
GO:0007155~cell adhesion 19 2.496715 2.87E-09 4.60E-06
GO:0010941~regulation of cell death 17 2.233903 1.04E-06 0.00166506
GO:0043067~regulation of programmed cell death 17 2.233903 9.88E-07 0.001585717
GO:0042981~regulation of apoptosis 17 2.233903 8.67E-07 0.0013906
GO:0042127~regulation of cell proliferation 17 2.233903 6.52E-07 0.001046319
GO:0007049~cell cycle 16 2.102497 2.94E-06 0.00471089
GO:0051270~regulation of cell motion 10 1.31406 3.26E-07 5.23E-04
GO:0040012~regulation of locomotion 10 1.31406 3.12E-07 5.01E-04
GO:0030334~regulation of cell migration 10 1.31406 1.05E-07 1.69E-04
down-regulated target gene GO functional annotation
GO:0042127~regulation of cell proliferation 13 2.901786 4.73E-07 7.26E-04
GO:0016265~death 12 2.678571 1.68E-06 0.00257469
GO:0008219~cell death 12 2.678571 1.57E-06 0.002405587
GO:0012501~programmed cell death 11 2.455357 2.87E-06 0.004409001
GO:0006915~apoptosis 11 2.455357 2.52E-06 0.003858936
Table 4 The KEGG-PATHWAY analysis of the target genes
Term Count % PValue
up-regulated target gene KEGG-
PATHWAY
hsa04520:Adherens junction 7 0.9198423 5.40E-06
hsa04510:Focal adhesion 7 0.9198423 0.001138399
hsa04512:ECM-receptor interaction 5 0.6570302 0.001552176
hsa04514:Cell adhesion molecules
(CAMs)
5 0.6570302 0.007927108
hsa04810:Regulation of actin
cytoskeleton
6 0.7884363 0.008917732
hsa05200:Pathways in cancer 7 0.9198423 0.012815044
hsa04530:Tight junction 4 0.5256242 0.047009212
hsa04120:Ubiquitin mediated
proteolysis
4 0.5256242 0.049654282
down-regulated target gene KEGG-PATHWAY
hsa05200:Pathways in cancer 8 1.7857143 1.12E-04
hsa04115:p53 signaling pathway 4 0.8928571 0.001901548
hsa04520:Adherens junction 4 0.8928571 0.002717119
hsa05210:Colorectal cancer 4 0.8928571 0.003481217
hsa04350:TGF-beta signaling pathway 4 0.8928571 0.003845193
hsa04110:Cell cycle 4 0.8928571 0.010537531
hsa04310:Wnt signaling pathway 4 0.8928571 0.017542982
hsa04510:Focal adhesion 4 0.8928571 0.036959365
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Page 7 of 12characterizing the molecular nature of disease but the
expense and limited specimen availability often lead to
studies with small sample sizes. This makes accurate
estimation of variability difficult. Since variance esti-
mates made on a gene-by-gene basis will have few
degrees of freedom, the assumption that all genes share
equal variance is unlikely to be true. To solve this pro-
blem, in this study, Multi-Class Dif was used which is
applicable to the small sample sizes and we found that
48 miRNAs were differentially expressed in the four
development stages and lymph node metastasis.
In our study, we present a global relative expression
analysis of miRNAs in NPC. miRNAs with similar
Figure 2 Target gene prediction of miRNAs. miRNA-gene interactions were built into a bipartite network (the miRNAome). The red rectangles
indicate the up-regulated miRNAs, the blue rectangles indicate the down-regulated miRNAs. The red ellipses indicate the up-regulated target
genes, the blue ellipses indicate the down-regulated target genes.
Figure 3 The expression miRNAs were verified by real-time
PCR in 38 NPC cases and 10 normal. (A) the up-regulated
miRNAs; (B) the down-regulated miRNAs.
Figure 4 The expression of corresponding target genes of
miRNAs were verified by real-time PCR in 38 NPC cases and 10
normal. (A) representative target genes of upregulated miRNAs; (B)
representative target genes of downregulated miRNAs.
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Page 8 of 12expression profiles are clustered together in 6 patterns
by cluster 3.0. In pattern 1, miRNA expressions gradu-
ally decreased during the development of NPC, which
may function as a tumor suppressor gene, such as miR-
29 [42,43]. In pattern 5, miRNA expressions gradually
increased during the development of NPC, such as miR-
18a/b. miR-18a/b was clustered together with miR-17-
92 [44,45] according to the similar expression profiles,
which were induced by c-myc and reported to promote
cell differentiation and proliferation. In pattern 6, such
as miR-206 [46] and miR-1 [47], miRNA expressions
dramatically increased in the lymph node metastasis. It
indicated that these miRNAs may play an important
role in the metastasis and may be a special biomarker
for the lymph node metastasis.
Bioinformatic algorithms have played a key role in the
discovery of miRNAs, prediction of target genes and
miRNAome. TargetScan, PicTar and miRanda were
commonly used to predict miRNA target genes. We
identified thousands of target genes in which only a
small fraction of miRNA are actually involved in the
biological process. The algorithms mentioned above
Table 5 The predicted transcription factors binding to the 48 aberrant miRNAs with the degree bigger than 10
Stage degree ≥ 10
I-II ETS2, MYB, Sp1, KLF6, NFE2, PCBP1, TMEM54
III ETS2, MYB, KLF6, Sp1, PCBP1, TMEM54, YY1, NFE2
IV ETS2, MYB, NFE2, PCBP1, APP, KLF6, Sp1, TMEM54, YY1, RUNX2, TFCP2, TEAD2, NR3C1, TFAP2A
Lymph node
metastasis
ETS2, MYB, NFE2, Sp1, YY1, KLF6, TMEM54, ESR1, PCBP1, APP, TEAD2, RUNX2, TFCP2, TFAP2A, MAZ, NR3C1, TBP, WT1, MYC,
AP1S1, USF1
Figure 5 The miRNA transcriptional network for NPC development. These transcription factor-miRNA interactions were built into a network.
The triangles represent transcription factors which regulate the miRNA expression; the squares represent the miRNAs which were regulated by
TFs. The larger triangles represent the more miRNAs which are regulated.
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Page 9 of 12showed limited consistency among predicted targets. It
is necessary to identify the confirmed target genes
which are actually related to the miRNA regulation
function. In this study, the thousands of target genes
were refined by screening with the nasopharyngeal- spe-
cifically expressed genes. Another data reduction strat-
egy is to compare the miRNA expression and cDNA
expression data and select the miRNA which is consis-
tent with the cDNA expression [48]. The cDNA expres-
sion data (GSE12452) were downloaded from the
publicly-accessible National Center for Biotechnology
Information-Gene Expression Omnibus (GEO). The
data reduction strategies narrowed down the target
miRNA list and promoted the accuracy of high-through-
put technology and bioinformatics. Using these data
reduction strategy, we narrowed down the miRNAs list,
showing that miR-29a/c, miR-34b/c, miR-429, miR-203,
miR-222, miR-1/206, miR-141, miR-18a/b, miR-544,
miR-205 and miR-149 may be the most important mod-
ulator during the development of NPC. The expressions
of these miRNAs were also validated using real-time
RT-PCR.
It is estimated that 1-4% of genes in the human gen-
ome encode miRNAs and a single miRNA can regulate
as many as 200 mRNAs [49]. The expression of miRNAs
can be activated or repressed by transcription factors
(TFs), which therefore can serve as upstream regulators
of miRNAs. In recent years, many researchers have
attempted to understand how miRNAs act to regulate
target genes and what their roles are in various diseases.
However, the study of miRNAs regulation by TFs (TF-
miRNA regulation) has been relatively limited. We
reported previously that miRNAs and TFs may coop-
erate to regulate target gene expression. In addition,
miRNAs and TFs can form feedback or feed-forward
loops, which play critical roles in various biological pro-
cesses. For example, ETS2 induces expression of miR-7
which, in turn, suppresses the expression of ETS2 activ-
ity. Increasing evidence suggests that aberrant regulation
of miRNAs by TFs can cause diseases. Therefore, TF-
miRNA regulation is one of the most important aspects
of the study of both miRNAs and TFs. In this study, we
bioinformatically predicted twenty-one TFs, seven of
which may be the key regulator of the miRNA expres-
sion. This study provides an initial valuable data set for
the miRNA regulation and its function.
Conclusions
The goal of profiling miRNA expression in this study is
to discover the specific miRNAs in which influence the
development of NPC. We found that miR-29a/c, miR-
34b, miR-34c-3p, miR-34c-5p, miR-429, miR-203, miR-
222, miR-1/206, miR-141, miR-18a/b, miR-544, miR-205
and miR-149 may play important roles in this respect.
Merging the mRNA expression array and building an
integrated molecular net-work associated with NPC
enables us to gain a better understanding of the overall
pathology. The transcription factors that including
ETS2, MYB, Sp1, KLF6, NFE2, PCBP1 and TMEM54
exert regulatory functions on the miRNA expression.
Three of them were predicted to repress their own
translation through a TF-miRNAs-gene feedback loop.
Bioinformatics and data filtering strategy were combined
to screen the miRNAs which may be the key modulator
in the process of tumorigenesis.
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